Jefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy

August 5, 2016 10:46 AM EDT
Get Alerts BMRN Hot Sheet
Price: $84.62 -1.78%

Rating Summary:
    20 Buy, 6 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade BMRN Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $120.00 (from $116.00), following the company's 2Q earnings report.

Analyst Eun Yang commented, "Higher 2Q revenue on higher Vimizim & Kuvan sales. With Naglazyme, Kuvan & Vimizim sales running at >$300M each in 2016, BMRN continues to expect nonGAAP breakeven or better in 2017 (breakeven at ~$1.2-1.3B in annual revenue, by our estimate). Assuming potential approval of Brineura in 1Q17 and of PEGPAL in 2018, we forecast a 5-yr revenue CAGR of ~24% thru 2020."

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $99.62 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Earnings

Add Your Comment